We recently reported that
hypoxia induces
chromatin condensation and cell nuclear fragmentation, morphological markers of apoptosis, to tube-forming HUVECs in an in vitro blood vessel model by activating
p38 MAPK. In this report, we further examined what role p38 plays and how it is activated during
hypoxia-induced apoptosis. First, in order to confirm that p38 can indeed induce apoptosis, the cells were treated with
anisomycin, a p38 activator, during normoxia. The activator treatment induced apoptosis and activation of p38 and
caspase-3 in a very short time, which indicated that p38 activation alone was sufficient to trigger apoptosis in tube-forming HUVECs. We then observed
hypoxia-induced changes in intracellular signals, ERK1/2 and Akt. ERK1/2 inactivation was shown to occur prior to p38 activation and
caspase-3 cleavage during
hypoxia. On the other hand,
anisomycin had no inhibitory effect on ERK1/2 activation during normoxia. It was also shown that the amount of Akt
protein slightly decreased by either
hypoxia or
anisomycin treatment. We then investigated how these two survival signals, ERK1/2 and Akt, are involved in p38 activation by using
MEK inhibitor
U0126 and PI3K inhibitor
LY294002. When tube-forming HUVECs were treated with
U0126 or
LY294002 during normoxia, the two inhibitors were able to induce apoptosis and activation of p38 and
caspase-3 in a relatively short time.
U0126 was able to inhibit ERK1/2 activation, but had almost no effect on Akt activation. In contrast,
LY294002 was able to inhibit Akt activation, but had very little effect on ERK1/2 activation. These results indicate that ERK1/2 inactivation, rather than Akt decrease, is responsible for
hypoxia-induced p38 activation. Taken together, our results strongly suggest that
hypoxia-induced apoptosis is regulated through signal transduction in which inactivation of ERK1/2 leads to activation of p38, which then triggers
caspase cascade as an execution mechanism of apoptosis.